Lupin Ltd.

LUPIN

Market Cap
₹74,572 Cr.
P/E
38.95

Lupin Ltd.

Quick View
  • 1d
  • 1m
  • 6m
  • YTD
  • 1y
  • 3y
  • 5y
  • 10y
  • max
locked

Company Timeline

Company Timeline

Subscribe now for more updates
Forensics

11 Yes

Positive for this company

1 Neutral

Neutral for this company

5 No

Negative for this company

0 No Data

Insufficient data to analyse

ROE
Latest
3.45%
3yr Average
-0.1%
5yr Average
0.39%
Net Profit Margin
Latest
2.58%
3yr Average
0.43%
5yr Average
0.74%
ROCE
Latest
7.32%
3yr Average
3.41%
5yr Average
6.39%
Debt to Equity
Latest
0.34
3yr Average
0.33
5yr Average
0.42
Market Share
7.98% (as of Jul 22)
Anti - Diabetes - Market Share
3.08% (as of Jul 22)
Anti-Infectives - Market Share
0.03% (as of May 19)
Anti-Malarial - Market Share
0.09% (as of Nov 21)
Antineo Plastic - Market Share
2.15% (as of Nov 21)
Blood Related - Market Share
6.74% (as of Jul 22)
Cardiovascular - Market Share
0.24% (as of Nov 21)
Dermatology - Market Share
0.48% (as of Nov 21)
Endocrinology - Market Share
2.48% (as of Jul 22)
Gastro-Intestinal - Market Share
3.06% (as of Nov 21)
Gynecology - Market Share
3.13% (as of Nov 21)
Neurological - Market Share
1.70% (as of Nov 21)
Ophthalmology - Market Share
2.06% (as of Nov 21)
Pain - Market Share
3.50% (as of Dec 22)
Pharmaceutical Sector - Market Share
6.35% (as of Nov 21)
Respiratory - Market Share
0.46% (as of Jul 22)
Sex Stimulants - Market Share
0.23% (as of Nov 21)
Stomatological - Market Share
18.70% (as of Mar 21)
Thyroid Hormone(Levothyroxine) - Market Share
locked Source
3.39% (as of Nov 21)
Urology - Market Share
0% (as of Jul 22)
Vaccines - Market Share
1.49% (as of Jul 22)
Vitamin & Dietary Supplements - Market Share
Show more
Revenue mix

Product Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Segment Break-Up

locked
Source
|
Latest
|
locked
Historic

Therapeutic Area Wise Break-Up - Domestic

locked
Source
|
Latest
|
locked
Historic

Location Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Acute vs Chronic

locked
Source
|
Latest
|
locked
Historic
Show more
Operational Metrics

    locked
    Select a Metric
    • US DMF Filings (.)
      Source
    • Number of ANDA's Filed in USA (.)
      Source
    • Number of ANDA's Approved By USFDA (.)
      Source
    • Domestic Sales Growth - YoY (%)
      Source
    • R&D as a % of Total Sales (%)
      Source
    Peer Comparison
    Suppliers
    Company Filing
    Show Previous Years
    Discussions & Analysis
    Lupin Ltd.
    View the discussion on ValuePickr
    Lupin - An Interesting Turnaround Story In Pharma Sector - Logical Investor
    Pharmaceutical Sector
    How The Pharma Industry Works - PPFAS
    Phama Industry - Terminologies and Value Chain - Alpha Invesco
    Deep Dive into Pharma Sector - Omkara Capital
    Pharma Compliance In-Depth - Amit Rajan
    Nutraceuticals - The Next Gem of Healthcare Sector - Shuchi Nahar
    Nutraceuticals- Industry Overview - Value Educator
    Generic Opportunity for Indian Pharma Companies - Anish Moonka
    timeline